GLP-1/GIP/glucagon triple agonist

Retatrutide

A once-weekly GIP, GLP-1 and glucagon receptor agonist from Eli Lilly that is still investigational, studied in trials funded by Eli Lilly. The phase 1b report gives its half-life as approximately 6 days. In the phase 3 TRIUMPH-1 trial, 12 mg weekly was followed by a mean body weight change of −25.0% at 80 weeks against −3.9% with placebo (treatment-regimen estimand).

Emerging evidenceGet the app

Level after one dose

Retatrutide after one dose: 50% at ~5 days, 25% at 10 days, 12.5% at 15 days.

Drawn from the half-life in the app's model, ~5 days. The model's figures

1

How Milligram users log it

Track your protocol with Milligram.

49%The most tracked compound in Milligram: of people who track compounds in Milligram logged Retatrutide in the last 90 days.

Schedule

  1. Daily6%
  2. Every other day7%
  3. Twice a week29%
  4. Weekly52%
  5. Less often6%
Among people with three or more logged doses, by the average gap between their doses.

Logged doses

Half of people logged between 1 and 4 mg per dose; the median was 2 mg.

Each person's usual logged amount. The bar starts at zero; the shaded part is the middle half, the mark the median.

Tracked alongside

The share of people logging Retatrutide who also logged each.

From dose logs in the Milligram app, 90 days to 15 November 2026. Aggregated and anonymous. This describes what people recorded, not what anyone should take.

Retatrutide, also written LY3437943 and shortened to reta, is an investigational triple agonist of the GIP, GLP-1 and glucagon receptors, given in trials as a once-weekly subcutaneous injection.1,2,3 Eli Lilly and Company funded the phase 1b, phase 2 and phase 3 trials reported below, and Lilly employees are among the authors of those reports.4,5,1,6 An FDA page current as of 1 October 2026 states that retatrutide has not been found safe and effective for any condition, and a Therapeutic Goods Administration (TGA) advisory of 14 September 2026 states that it has not been approved by the TGA or any comparable international regulator.7,8 Peer-reviewed phase 3 reports published from June to November 2026 cover type 2 diabetes (TRANSCEND-T2D-1), obesity without and with type 2 diabetes (TRIUMPH-1, TRIUMPH-2) and knee osteoarthritis (TRIUMPH-4).9,3,6,2

3

How it works

The phase 1 report describes retatrutide as a single triple agonist peptide acting at the glucagon, GIP and GLP-1 receptors.4 In obese mice it decreased body weight, and the authors state that weight loss was augmented by glucagon receptor-mediated increases in energy expenditure added to calorie intake reduction driven by the GIP and GLP-1 receptors.4 A 2026 review states that glucagon receptor signalling influences energy expenditure particularly in rodents, and that in people clinical glycaemic improvement supports the net efficacy of the combined molecule rather than establishing a separately quantified benefit for each receptor.10

4

Pharmacokinetics

Values from the Milligram app's model.

Half-life
~5 days
Bioavailability
95%
mg/week typical
0.5–12
Route
SubQ
Table 4.1Pharmacokinetics6 rows
ParameterValueNote
Half-life5,10,11120 hours (about 5 days)The phase 1b report states approximately 6 days; a 2026 review reports 134 to 165 hours (geometric mean terminal) in the first-in-human study; volunteers with well-fitted models had estimates of 5.5 to 9.6 days (mean about 7.5).
Time to peak10,1148 hoursMedian time to maximum concentration was 12 to 72 hours by cohort in the first-in-human study; peaks typically came 24 to 48 hours after the first dose in four self-administering volunteers.
Bioavailability (SubQ)95%No bioavailability figure is reported in the sources cited.
Route1,3SubcutaneousOnce weekly in trials.
Steady state10Expected to approach steady state in roughly 3.5 to 4.5 weeks of weekly dosing (a calculation, not measured)A review calculation from a 6-day half-life.
Detection and urine11Plasma still detectable 56 days after the first dose (estimated 7.1 to 38.4 ng/mL); no intact retatrutide or expected cleavage-product signals in urineFour volunteers who self-administered 2 mg on days 1 and 7; the authors describe the concentrations as semi-quantitative estimates.

A 2026 review states that accumulation ratios, steady-state trough concentrations and a population pharmacokinetic model are not reported in the sources it reviewed, and that dedicated studies in renal or hepatic impairment have not been published.10

5

Human studies

Table 5.1Human studies10 rows
Study and yearDesignPeopleDose and lengthMain result
Phase 1, Coskun 20224,10Single ascending dose45 healthy participants0.1 to 6 mg subcutaneous, one doseLilly-employed authors report a safety profile similar to other incretins; body weight reduction persisted up to day 43.
Phase 1b, Urva 20225Lilly-funded, randomised, double-blind, placebo- and dulaglutide-controlled; primary outcome safety and tolerability72 adults with type 2 diabetes0.5 to 12 mg weekly (five cohorts), 12 weeksAdverse events in 63% on retatrutide, 60% on dulaglutide, 54% on placebo; 29 of 72 (40%) left the study early (arm not stated); placebo-adjusted HbA1c, a secondary outcome, fell significantly in the three highest dose groups (−1.4% [90% CI −2.17 to −0.56], −1.6% [−2.37 to −0.75], −1.2% [−2.05 to −0.45]).
Phase 2 obesity, Jastreboff 20231Lilly-funded, randomised, double-blind, placebo-controlled338 adults with a BMI of 30 or more, or 27 to under 30 with a weight-related condition1, 4, 8 or 12 mg weekly, 48 weeksWeight at 24 weeks (primary): −7.2%, −12.9%, −17.3%, −17.5% against −1.6% with placebo; at 48 weeks −8.7%, −17.1%, −22.8%, −24.2% against −2.1%. Gastrointestinal events were dose related; dose-dependent heart rate increases peaked at 24 weeks and declined thereafter.
Phase 2 diabetes, Rosenstock 202312Lilly-funded, randomised, double-blind, placebo- and dulaglutide-controlled281 adults with type 2 diabetes0.5, 4, 8 or 12 mg weekly; HbA1c at 24 weeks, weight at 36 weeksHbA1c (primary) −0.43% with 0.5 mg to −2.02% with 12 mg, against −0.01% with placebo and −1.41% with dulaglutide; significantly greater than placebo except at 0.5 mg, and greater than dulaglutide in the 8 mg slow-escalation and 12 mg groups. Weight at 36 weeks −3.19% (0.5 mg) to −16.94% (12 mg) against −3.00% with placebo.
MASLD substudy, Sanyal 202413Randomised, double-blind, placebo-controlled substudy of the obesity trial98 adults with metabolic dysfunction-associated steatotic liver disease (MASLD) and liver fat of 10% or more1, 4, 8 or 12 mg weekly, 48 weeksLiver fat at 24 weeks (primary): −42.9%, −57.0%, −81.4%, −82.4% against +0.3% with placebo; normal liver fat (<5%) in 27%, 52%, 79% and 86% against 0%. Mean ALT, AST, FIB-4 and ELF did not change consistently against placebo.
TRANSCEND-T2D-1, 20269Lilly-funded, randomised, double-blind, placebo-controlled phase 3537 adults with type 2 diabetes inadequately controlled by diet and exercise4, 9 or 12 mg weekly, 40 weeksHbA1c (primary, treatment-regimen estimand) −1.69%, −1.86%, −1.94% against −0.81% with placebo; weight −11.5%, −13.9%, −15.3% against −2.6%; discontinuation due to adverse events 2 to 5% against 0%; two deaths, both on 4 mg and unrelated to the study drug.
TRIUMPH-1, 20263Lilly-funded, randomised, double-blind, placebo-controlled phase 32339 adults with obesity, without diabetes4, 9 or 12 mg weekly, 80 weeksWeight −17.6%, −23.7%, −25.0% against −3.9% with placebo (treatment-regimen estimand); the most common adverse events were gastrointestinal.
TRIUMPH-2, 20266Lilly-funded, randomised, double-blind, placebo-controlled phase 31152 adults with obesity and type 2 diabetes4, 9 or 12 mg weekly, 80 weeksWeight −11.9%, −16.8%, −18.8% against −5.1% with placebo (treatment-regimen estimand); permanent discontinuation due to adverse events or death 4%, 12% and 8% against 5%.
TRIUMPH-3, no full report10Randomised, double-blind, placebo-controlled phase 3; sponsor topline figures as reported by a 2026 review1949 adults with BMI of 35 or more and established cardiovascular disease, with or without diabetes9 mg, 12 mg or placebo (1:1:2), 80 weeksWeight −21.6% and −22.6% against −3.2% (efficacy estimand, which differs from the treatment-regimen estimand used above). In-study MACE-5 hazard ratio 0.82 (95% CI 0.55 to 1.22; 44 against 52 events), MACE-3 1.12 (0.64 to 1.96; 27 against 23 events); the review states neither estimate establishes cardiovascular benefit or excludes clinically relevant harm.
TRIUMPH-4, 20262Lilly-funded, randomised, placebo-controlled phase 3445 adults without diabetes with painful knee osteoarthritis and BMI of 27 or more9 or 12 mg weekly, 68 weeksWOMAC pain (0 to 10) difference from placebo: −1.83 (9 mg) and −1.61 (12 mg) with the hybrid estimand, −1.70 and −1.38 with the intention-to-treat estimand; weight −20.0% (9 mg) and −23.7% (12 mg) against −4.6%. In TRIUMPH-4 and TRIUMPH-1-OA, serious adverse events were more common with retatrutide than with placebo.

In the phase 2 and phase 3 obesity trials the reported weight change was larger at higher doses: −24.2% with 12 mg at 48 weeks against −2.1% with placebo in the phase 2 trial, and −25.0% against −3.9% at 80 weeks in TRIUMPH-1.1,3

Some results were null or uncertain: in the phase 2 diabetes trial the 0.5 mg group did not differ significantly from placebo on HbA1c, with weight falling 3.19% against 3.00% with placebo at 36 weeks (no test for this comparison is reported in the source quoted), and the TRIUMPH-3 in-study cardiovascular estimates were imprecise.12,10

6

Doses reported in studies and on labels

Trials gave 0.5 to 12 mg weekly (phase 1 single doses started at 0.1 mg), and no dose is approved.12,1,10,7 Retatrutide has no label dose, because the FDA page current as of 1 October 2026 states that it is not a component of an FDA-approved drug.7

Table 6.1Doses reported in studies and on labels8 rows
SourceDoseFrequencyLength
Phase 1 (Coskun 2022)10,40.1 to 6 mg subcutaneousSingle doseOne dose, weight followed to day 43
Phase 1b (Urva 2022)50.5, 1.5, 3, 3/6 and 3/6/9/12 mgOnce weekly12 weeks
Phase 2 obesity (Jastreboff 2023)11, 4, 8 or 12 mg maintenance; some groups started at 2 mg or 4 mgOnce weekly48 weeks
Phase 2 diabetes (Rosenstock 2023)120.5, 4, 8 or 12 mg maintenance, several escalation schedulesOnce weeklyPrimary endpoint at 24 weeks, secondary at 36 weeks
TRIUMPH-1, TRIUMPH-2 and TRANSCEND-T2D-13,6,94, 9 or 12 mgOnce weekly80 weeks (TRANSCEND-T2D-1: 40 weeks)
TRIUMPH-429 or 12 mgOnce weekly68 weeks (primary endpoints)
Phase 3 escalation, per a 2026 review10Start at 2 mg, then 2 to 4 mg; 2 to 4 to 6 to 9 mg; or 2 to 4 to 6 to 9 to 12 mgOnce weekly, stepping up every 4 weeksPer trial arm
Four volunteers outside a trial (anti-doping study)112 mg subcutaneous, self-administered (product obtained by the volunteers)Days 1 and 7Two doses, sampled over 56 days

The most common adverse events in the phase 2 and phase 3 trials were gastrointestinal.1,3,6,9 In the phase 2 obesity trial these events were dose related, mostly mild to moderate and partially mitigated by a lower starting dose (2 mg compared with 4 mg).1 The trial's registry results list nausea in 28 of 62 participants at 12 mg and 21 of 35 in the 8 mg group that started at 4 mg, against 8 of 70 with placebo, and vomiting in 12 of 62 against 1 of 70.14

In TRIUMPH-2, diarrhoea occurred in 27%, 34% and 34% of participants at 4, 9 and 12 mg against 13% with placebo, and nausea in 14%, 21% and 28% against 8%.6 Hypotension (1%, 5% and 6% against less than 1%) and dysesthesia (4%, 6% and 7% against 1%) were more frequent with retatrutide than with placebo.6 Permanent discontinuation due to adverse events or death was 4% at 4 mg, 12% at 9 mg and 8% at 12 mg against 5% with placebo, and seven participants died (two, three and one on retatrutide and one on placebo), all judged by the investigator to be unrelated to the study intervention.6 In TRANSCEND-T2D-1, discontinuations due to adverse events were 2 to 5% with retatrutide and 0% with placebo, and no severe hypoglycaemia was reported.9

In the phase 2 obesity trial's registry record, adverse events led to withdrawal in 2 of 62 participants at 12 mg and none of 70 on placebo, and one participant in a 4 mg group died, with one serious event of drowning listed in the same group.14 Serious events listed there, without a stated cause, include acute pancreatitis (1 of 62 at 12 mg), electrocardiogram QT prolonged (1 of 62 at 12 mg), cardiac failure (1 of 35 in one 8 mg group) and acute cholecystitis (1 of 35 in the other 8 mg group).14 In the MASLD substudy, two participants given retatrutide (2.5%) had three serious adverse events in total, and the authors report no hepatotoxicity signals through 48 weeks.13

Heart rate

In the phase 2 obesity trial, dose-dependent increases in heart rate peaked at 24 weeks and declined thereafter.1 A 2026 review states that attribution of this specifically to glucagon receptor agonism is uncertain, and calls for evaluation of resting heart rate, arrhythmias, symptoms, treatment exposure and adjudicated cardiovascular events.10

Sponsor topline rates reported by the review

The review reports sponsor topline figures that are not from peer-reviewed trial reports and which it describes as provisional pending full published reports: in TRIUMPH-1, nausea in 28.6%, 38.4% and 42.4% at 4, 9 and 12 mg against 14.8% with placebo, dysaesthesia in 5.1%, 12.3% and 12.5% against 0.9%, and discontinuation due to adverse events in 4.1%, 6.9% and 11.3% against 4.9%.10 For TRIUMPH-4 it reports, at 9 and 12 mg, dysaesthesia in 8.8% and 20.9% against 0.7% with placebo and discontinuation due to adverse events in 12.2% and 18.2% against 4.0%, and says the sponsor described greater discontinuation among participants with lower baseline BMI, including perceived excessive weight loss.10 The review lists pancreatitis, gallbladder events, severe gastrointestinal intolerance, aspiration during anaesthesia, retinopathy changes accompanying rapid glycaemic improvement and thyroid C-cell findings as areas for assessment.10

Blood glucose: the phase 1b trial reported placebo-adjusted decreases in mean daily plasma glucose of 2.8, 3.1 and 2.9 mmol/L at week 12 in the 3 mg, 3/6 mg and 3/6/9/12 mg groups.5 HbA1c was the primary endpoint of the phase 2 diabetes trial at 24 weeks and of TRANSCEND-T2D-1 at 40 weeks.12,9 Body weight was the primary endpoint of the phase 2 obesity trial (percentage change at 24 weeks) and of TRIUMPH-2 (percentage change at week 80).1,6 Other markers measured in studies: in the MASLD substudy, ALT, AST, FIB-4 and ELF did not change consistently against placebo, while K-18 decreased significantly with 8 mg at 24 weeks and with 8 and 12 mg at 48 weeks.13

The FDA page current as of 1 October 2026 states that retatrutide and cagrilintide cannot be used in compounding under federal law.7 It also states that the FDA has warned companies that sold unapproved drugs containing retatrutide and other GLP-1 compounds falsely labelled “for research purposes” or “not for human consumption”, and urges consumers not to purchase these products, which it describes as of unknown quality.7 A 2026 review reports that Lilly announced in July 2026 a plan to submit a Biologics License Application in the United States in the first quarter of 2027, and says this is a sponsor-stated plan and not regulatory acceptance of a filing.10 A European Medicines Agency paediatric investigation plan decision of 13 September 2024 covers retatrutide for the treatment of obesity and records, as information provided by the applicant, that the product is not authorised anywhere in the European Community.15 The TGA advisory of 14 September 2026 states that any retatrutide product accessed outside clinical trials could be counterfeit, advises against use outside a clinical trial setting, and reports a sample sold as retatrutide that contained undeclared semaglutide and no retatrutide.8

Anti-doping

The WADA Prohibited List page does not name retatrutide. Section S0 of the list prohibits at all times any pharmacological substance not addressed by other sections and with no current approval by any governmental regulatory health authority for human therapeutic use, with drugs under pre-clinical or clinical development given as an example, and the WADA FAQ states that a substance is included in S0 on rare occasions, after a case-by-case evaluation.16 The authors of a 2026 anti-doping study cite concerns about potential misuse in sport, and conclude that plasma is the appropriate matrix for detection because no retatrutide signals were detected in urine.11

10

Storage and handling

The FDA page current as of 1 October 2026 states that retatrutide is not a component of an FDA-approved drug, so there is no FDA label storage statement to quote.7

Retatrutide's indications, contraindications and prescribing instructions have not been set by a regulator, and the 2026 review states that they require regulatory review.10 At its 11 September 2026 evidence cutoff the review states that TRIUMPH-1 to TRIUMPH-4 results derived from sponsor topline disclosures and congress presentations, and it states that the TRIUMPH-1 104-week extension, limited to 532 participants who tolerated treatment, cannot be read as an unselected placebo-controlled effect.10 PubMed lists one record for retatrutide and TRIUMPH-3 as of 15 November 2026, a trial design paper, so the TRIUMPH-3 figures above are the review's account of sponsor topline results.17 The review states that a dedicated outcomes trial is needed to clarify cardiovascular and renal outcomes, and that rare events, pregnancy exposure and long-term effects require larger datasets and dedicated follow-up.10 The detection and urine findings come from four volunteers who obtained and self-administered the product themselves.11 The review states that the contribution of each receptor to the clinical effect has not been separately quantified.10

What is the half-life of retatrutide?

Retatrutide's half-life is approximately 6 days in the phase 1b report, and a 2026 review reports 134 to 165 hours in the first-in-human single-dose study.5,10 Four volunteers who injected 2 mg themselves had estimated terminal half-lives of about 5.5 to 9.6 days (mean about 7.5).11

How long does retatrutide stay in the body?

In four volunteers who obtained and injected 2 mg themselves (identity confirmed by the authors), semi-quantitative plasma estimates were 7.1 to 38.4 ng/mL at day 56, which is a detection finding in four people, not a clearance time.11 No intact retatrutide or expected cleavage-product signals were detected in their urine.11

What dose of retatrutide was used in the phase 2 trial?

The phase 2 obesity trial used maintenance doses of 1, 4, 8 and 12 mg once weekly for 48 weeks, with some groups starting at 2 or 4 mg.1 The phase 2 trial in type 2 diabetes used maintenance doses of 0.5, 4, 8 and 12 mg once weekly; these were doses given to trial participants, and no dose is approved.12,7

How much weight did people lose on retatrutide in trials?

In TRIUMPH-1 the mean body weight change at 80 weeks was −17.6% at 4 mg, −23.7% at 9 mg and −25.0% at 12 mg, against −3.9% with placebo.3 These are treatment-regimen estimand results from 2339 adults with obesity without diabetes; in TRIUMPH-2, in adults with type 2 diabetes, the changes were −11.9%, −16.8% and −18.8% against −5.1%.3,6

What are the side effects of retatrutide in trials?

The most common adverse events were gastrointestinal: in TRIUMPH-2, diarrhoea occurred in 27% to 34% and nausea in 14% to 28% of retatrutide participants against 13% and 8% with placebo.6,1 In TRIUMPH-2, permanent discontinuation due to adverse events or death was 4%, 12% and 8% against 5% and deaths were judged unrelated by the investigator; serious adverse events were more common than with placebo in the knee osteoarthritis trials, and the phase 2 obesity trial reported dose-dependent heart rate increases.6,2,1

Is retatrutide FDA approved?

As of the FDA page current on 1 October 2026, retatrutide is not FDA approved.7 An FDA page current as of 1 October 2026 states that it has not been found safe and effective for any condition and cannot be used in compounding under federal law.7

Is retatrutide banned in sport?

Retatrutide is not named on the WADA Prohibited List page, whose section S0 prohibits at all times substances with no current regulatory approval for human therapeutic use, such as drugs in clinical development.16 The same page states that a substance is included in S0 on rare occasions, after a case-by-case evaluation, and a 2026 anti-doping study reports detection of retatrutide in plasma, not urine, in four volunteers.16,11

14

References

  1. Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. N Engl J Med 2023. PMID 37366315
  2. Schnitzer TJ, et al. Retatrutide Once Weekly in Adults with Knee Osteoarthritis Pain and Obesity. N Engl J Med 2026. PMID 43001755
  3. Jastreboff AM, et al. Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity. N Engl J Med 2026. PMID 42814954
  4. Coskun T, et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept. Cell Metab 2022. PMID 35985340
  5. Urva S, et al. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial. Lancet 2022. PMID 36354040
  6. Bellido V, et al. Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial. Lancet 2026. PMID 42810372
  7. US Food and Drug Administration. FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss Web page, content current as of 1 October 2026. fda.gov
  8. Therapeutic Goods Administration (Australia). TGA tests counterfeit retatrutide product following serious adverse event report. Safety advisory, 14 September 2026. tga.gov.au
  9. Bajaj HS, et al. Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial. Lancet 2026. PMID 42250575
  10. Mateescu DM, et al. Retatrutide as a Unimolecular GIP/GLP-1/Glucagon Receptor Tri-Agonist: Molecular Design, Pharmaceutical Development and Critical Interpretation of Emerging Phase 3 Evidence. Pharmaceutics 2026. PMC13708278
  11. Carneiro GRA, et al. Detection and Excretion Profile of Retatrutide in Human Plasma and Urine by LC-HRMS: Implications for Antidoping Analysis. Rapid Commun Mass Spectrom 2026. PMC13578828
  12. Rosenstock J, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. Lancet 2023. PMID 37385280
  13. Sanyal AJ, et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nat Med 2024. PMC11271400
  14. Eli Lilly and Company (sponsor). A Study of LY3437943 in Participants Who Have Obesity or Are Overweight. Registry record, last update posted 13 Sep 2023. NCT04881760
  15. European Medicines Agency. European Medicines Agency decision P/0336/2024 of 13 September 2024 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for retatrutide (EMEA-003258-PIP02-23) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council EMA decision, 2024. ema.europa.eu
  16. World Anti-Doping Agency. The Prohibited List Web page. wada-ama.org
  17. Giblin K, et al. Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials. Diabetes Obes Metab 2026. PMID 41090431